Analysis of Trial Data for Infliximab and Golimumab: Baseline C-Reactive Protein Level and Prediction of Therapeutic Response in Patients With Psoriatic Arthritis

Clinical Response, Drug Survival, and Predictors Thereof Among 548 Patients With Psoriatic Arthritis Who Switched Tumor Necrosis Factor α Inhibitor Therapy: Results from the Danish Nationwide DANBIO Registry

(2013) Bente Glintborg et al.   ARTHRITIS AND RHEUMATISM

Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn’s disease

(2013) W. J. Sandborn et al.   CURRENT MEDICAL RESEARCH AND OPINION

Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis

(2013) S. Fénix-Caballero et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab

(2012) Carrie L Wagner et al.   ANNALS OF THE RHEUMATIC DISEASES

Artrite psoriásica: entidade clínica distinta da psoríase?

(2012) Danilo Garcia Ruiz et al.   Revista Brasileira De Reumatologia

Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: Results from the nationwide Danish DANBIO registry

(2010) Bente Glintborg et al.   ARTHRITIS AND RHEUMATISM

Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis

(2010) V. Chandran et al.   RHEUMATOLOGY

Sustained Clinical Response in Psoriatic Arthritis Patients Treated with Anti-TNF Agents: A 5-year Open-Label Observational Cohort Study

(2010) Ioanna Saougou et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid A protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis

(2009) Mirjam K. de Vries et al.   ARTHRITIS AND RHEUMATISM

Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

(2009) Arthur Kavanaugh et al.   ARTHRITIS AND RHEUMATISM